| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A Laakso, J Bergman, M Haaparanta, H Vilkman, O Solin, E Syvälahti, J Hietal. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophrenia research. vol 52. issue 1-2. 2001-12-18. PMID:11595398. |
together with the finding of unchanged average striatal dat levels in first-episode patients and relative insensitivity of striatal [18f]cft binding to endogenous dopamine and neuroleptic drugs, the result is in line with a relative loss of striatal dopaminergic nerve terminals and/or decreased expression of dat in a subset of chronic schizophrenic patients. |
2001-12-18 |
2023-08-12 |
Not clear |
| H W Berendse, J Booij, C M Francot, P L Bergmans, R Hijman, J C Stoof, E C Wolter. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Annals of neurology. vol 50. issue 1. 2001-12-14. PMID:11456307. |
single photon emission computed tomography (spect) with [123i]beta-cit as a dopamine transporter ligand was used to assess nigrostriatal dopaminergic function in 25 hyposmic and 23 normosmic relatives of pd patients. |
2001-12-14 |
2023-08-12 |
human |
| M A Volonté, R M Moresco, C Gobbo, C Messa, A Carpinelli, G Rizzo, G Comi, F Fazi. A PET study with [11-C]raclopride in Parkinson's disease: preliminary results on the effect of amantadine on the dopaminergic system. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 22. issue 1. 2001-12-13. PMID:11487182. |
the aim of this study was to evaluate the effects of amantadine on the dopaminergic system by measuring the in vivo binding of [11-c]raclopride to d2 dopamine receptors in the basal ganglia of 6 patients with idiopathic parkinson's disease. |
2001-12-13 |
2023-08-12 |
rat |
| A Antonini, R M Moresco, C Gobbo, R De Notaris, A Panzacchi, P Barone, S Calzetti, A Negrotti, G Pezzoli, F Fazi. The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 22. issue 1. 2001-12-13. PMID:11487195. |
neuroimaging studies of the striatal dopamine transporter (dat) are useful in the assessment of the dopaminergic system in parkinson's disease (pd). |
2001-12-13 |
2023-08-12 |
human |
| F Stocchi, L Vacca, M F De Pandis, L Barbato, M Valente, S Ruggier. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 22. issue 1. 2001-12-13. PMID:11487217. |
continuous dopaminergic stimulation can be achieved more easily by infusing dopamine agonists subcutaneously. |
2001-12-13 |
2023-08-12 |
Not clear |
| S Lahlo. Central bromocriptine-induced tachycardia is reversed to bradycardia in conscious, deoxycorticosterone acetate-salt hypertensive rats. Pharmacology & toxicology. vol 88. issue 5. 2001-12-12. PMID:11393583. |
these results indicate that, in deoxycorticosterone acetate-salt hypertensive rats, bromocriptine decreases rather than increases heart rate, an effect that is mediated partly through a peripheral d2 dopaminergic mechanism and partly through stimulation of spinal dopamine d2 receptors. |
2001-12-12 |
2023-08-12 |
rat |
| S Lindholm, Rosin A, I Dahlin, J Georgieva, J Franc. Ethanol administration potentiates cocaine-induced dopamine levels in the rat nucleus accumbens. Brain research. vol 915. issue 2. 2001-12-12. PMID:11595207. |
acute administration of ethanol or cocaine increases the extracellular dopamine (da) concentration in the nucleus accumbens (nacc), a terminal region of the mesolimbic dopaminergic pathway. |
2001-12-12 |
2023-08-12 |
rat |
| C E Clarke, K H Dean. Cabergoline for levodopa-induced complications in Parkinson's disease. The Cochrane database of systematic reviews. issue 1. 2001-12-07. PMID:11279720. |
it is thought that dopamine agonists can reduce the duration of immobile off periods and the need for levodopa therapy whilst maintaining or improving motor impairments and only minimally increasing dopaminergic adverse events. |
2001-12-07 |
2023-08-12 |
Not clear |
| C E Clarke, K D Dean. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. The Cochrane database of systematic reviews. issue 1. 2001-12-07. PMID:11279721. |
it is thought that dopamine agonists can reduce the duration of immobile off periods and the need for levodopa therapy whilst maintaining or improving motor impairments and only minimally increasing dopaminergic adverse events. |
2001-12-07 |
2023-08-12 |
Not clear |
| K Tatsc. Imaging of the dopaminergic system in parkinsonism with SPET. Nuclear medicine communications. vol 22. issue 7. 2001-12-07. PMID:11453057. |
in recent years spet investigations of the dopamine transporter and of the dopamine d2-like receptors have provided valuable information about the pre- and postsynaptic dopaminergic system in parkinsonism. |
2001-12-07 |
2023-08-12 |
Not clear |
| I W Jones, J P Bolam, S Wonnacot. Presynaptic localisation of the nicotinic acetylcholine receptor beta2 subunit immunoreactivity in rat nigrostriatal dopaminergic neurones. The Journal of comparative neurology. vol 439. issue 2. 2001-12-07. PMID:11596051. |
these results demonstrate the presynaptic localisation of an nachr subunit in nigrostriatal dopaminergic neurones, providing morphological evidence for the presynaptic nicotinic modulation of dopamine release. |
2001-12-07 |
2023-08-12 |
rat |
| A Kaiser, M Fedrowitz, U Ebert, E Zimmermann, H J Hedrich, D Wedekind, W Lösche. Auditory and vestibular defects in the circling (ci2) rat mutant. The European journal of neuroscience. vol 14. issue 7. 2001-12-07. PMID:11683905. |
we have previously found that ci2/ci2 rats of both genders have a lower tissue content of dopamine in the striatum ipsilateral to the preferred direction of rotation, indicating that the rats turn away from the brain hemisphere with higher striatal dopaminergic activity. |
2001-12-07 |
2023-08-12 |
mouse |
| M J Bek, G M Eisner, R A Felder, P A Jos. Dopamine receptors in hypertension. The Mount Sinai journal of medicine, New York. vol 68. issue 6. 2001-12-07. PMID:11687863. |
this review summarizes the physiology and pathophysiology of the peripheral dopaminergic system and our current understanding of the role of individual dopamine receptors in the pathophysiology of human essential hypertension. |
2001-12-07 |
2023-08-12 |
human |
| E Shamir, Y Barak, I Shalman, M Laudon, N Zisapel, R Tarrasch, A Elizur, R Weizma. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Archives of general psychiatry. vol 58. issue 11. 2001-12-07. PMID:11695951. |
the pineal hormone melatonin is a potent antioxidant and attenuates dopaminergic activity in the striatum and dopamine release from the hypothalamus. |
2001-12-07 |
2023-08-12 |
Not clear |
| K R Sidell, S J Olson, J J Ou, Y Zhang, V Amarnath, T J Montin. Cysteine and mercapturate conjugates of oxidized dopamine are in human striatum but only the cysteine conjugate impedes dopamine trafficking in vitro and in vivo. Journal of neurochemistry. vol 79. issue 3. 2001-12-07. PMID:11701754. |
recent results have suggested that some products of mercapturic acid pathway (map) metabolism of oxidized dopamine (da) may contribute to mesostriatal dopaminergic neurodegeneration, and that at least one product, 5-s-cysteinyldopamine (cys-da), is elevated in patients with advanced parkinson's disease (pd) who have been treated with l-dopa. |
2001-12-07 |
2023-08-12 |
human |
| J T Trevitt, B B Carlson, K Nowend, J D Salamon. Substantia nigra pars reticulata is a highly potent site of action for the behavioral effects of the D1 antagonist SCH 23390 in the rat. Psychopharmacology. vol 156. issue 1. 2001-12-05. PMID:11465631. |
considerable evidence indicates that dopaminergic drugs, including drugs that act on d1 receptors, exert their effects by actions on forebrain dopamine terminal regions. |
2001-12-05 |
2023-08-12 |
rat |
| E Nann-Vernotica, E C Donny, G E Bigelow, S L Wals. Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacology. vol 155. issue 4. 2001-12-04. PMID:11441423. |
dopaminergic compounds have been targeted as potential treatments for cocaine abuse because of the known role of dopamine systems in drug reinforcement. |
2001-12-04 |
2023-08-12 |
human |
| K M Erikson, B C Jones, E J Hess, Q Zhang, J L Bear. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. Pharmacology, biochemistry, and behavior. vol 69. issue 3-4. 2001-12-04. PMID:11509198. |
the objective of this study was to determine the extent of functional alterations in dopamine receptors in two dopaminergic tracts in young, growing, iron-deficient rats. |
2001-12-04 |
2023-08-12 |
rat |
| B S Shastr. Parkinson disease: etiology, pathogenesis and future of gene therapy. Neuroscience research. vol 41. issue 1. 2001-12-04. PMID:11535288. |
although use of levodopa or dopamine agonists can substantially reduce clinical symptoms, and transplantation of fetal nerve tissue still remains as an alternative therapy (although it has been recently shown to be having no overall benefit), directed delivery of glial cell derived neurotrophic factor (known to have trophic effects on dopaminergic neurons) may also be a beneficial therapeutic option for pd patients. |
2001-12-04 |
2023-08-12 |
Not clear |
| A Heller, N Bubula, A Freeney, L Wo. Elevation of fetal dopamine following exposure to methamphetamine in utero. Brain research. Developmental brain research. vol 130. issue 1. 2001-12-04. PMID:11557103. |
this increase in fetal dopamine is consistent with our findings that exposure to methamphetamine in utero results in adult dopaminergic neurons which are more responsive in terms of methamphetamine induced release of the neurotransmitter and more sensitive to the neurotoxic effects of the drug. |
2001-12-04 |
2023-08-12 |
mouse |